KRAS-variant is a biomarker of cetuximab response potentially through altered immunity in head and neck cancer: Re-analysis of NRG Oncology/RTOG 0522

By J. Weidhaas, J. Harris, D. Schaue, Allen M. Chen, R. Chin, R. Axelrod, A. El-Naggar, Anurag K. Singh, T. Galloway, D. Raben and 12 more. 2017